Highlights of This Issue 709

THERAPEUTIC DISCOVERY

711 hTERT Promotes Imatinib Resistance in Chronic Myeloid Leukemia Cells: Therapeutic Implications
Laure Deville, Josette Hillion, Frédéric Pendino, Mona Samy, Eric Nguyen, and Evelyne Ségal-Bendirdjian

720 Modulation of Protein Phosphatase 2A Activity Alters Androgen-Independent Growth of Prostate Cancer Cells: Therapeutic Implications
Arun Bhardwaj, Seema Singh, Sanjeev K. Srivastava, Richard E. Honkanen, Eddie Reed, and Ajay P. Singh

732 CCN1, a Candidate Target for Zoledronic Acid Treatment in Breast Cancer
Ingrid Espinoza, Hong Liu, Robert Busby, and Ruth Lupu

742 A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers
Michael Faibish, Ralph Francescone, Brooke Bentley, Wei Yan, and Rong Shao

752 Evaluating the Consistency of Differential Expression of MicroRNA Detected in Human Cancers
Xue Gong, Ruihong Wu, Hongwei Wang, Xinwu Guo, Dong Wang, Yunyan Gu, Yuannv Zhang, Wenyuan Zhao, Lixin Cheng, Chenguang Wang, and Zheng Guo

761 Enhanced Chemotherapy of Cancer Using pH-Sensitive Mesoporous Silica Nanoparticles to Antagonize P-Glycoprotein–Mediated Drug Resistance
I-Ping Huang, Shu-Pin Sun, Shih-Hsun Cheng, Chia-Hung Lee, Chia-Yan Wu, Chung-Shi Yang, Leu-Wei Lo, and Yiu-Kay Lai

770 An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGF-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding

784 Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Kin Fan On, Yue Chen, Hoi Tang Ma, Jeremy P.H. Chow, and Randy Y.C. Poon

806 Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Deepak Raina, Michio Kosugi, Rehan Ahmad, Govind Panchamoorthy, Hasan Rajabi, Maroof Alam, Takeshi Shimamura, Geoffrey I. Shapiro, Jeffrey Supko, Surender Kharbanda, and Donald Kufe

817 Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Maurizio Scaltriti, Violeta Serra, Emmanuel Normant, Marta Guzman, Olga Rodriguez, Alice R. Lim, Kelly L. Siocum, Kip A. West, Varenka Rodriguez, Ludmila Prudkin, José Jimenez, Claudia Aura, and José Baselga

825 High-Throughput Screen Identifies Novel Inhibitors of Cancer Biomarker α-Methylacyl Coenzyme A Racemase (AMACR/P504S)
Brice A.P. Wilson, Haofan Wang, Benjamin A. Nacev, Ronnie C. Mease, Jun O. Liu, Martin G. Pomper, and William B. Isaacs
PRECLINICAL DEVELOPMENT

839 Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol
Jenna L. Riffell, Reiner U. Jänicke, and Michel Roberge

850 A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression
Franziska van Zijl, Sabine Mall, Georg Machat, Christine Pirker, Robert Zeillinger, Andreas Weinhaeuse, Martin Bilban, Walter Berger, and Wolfgang Mikulits

861 Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family

874 2-Methoxyestradiol Analogue ENMD-1198 Reduces Breast Cancer-Induced Osteolysis and Tumor Burden Both In Vitro and In Vivo
Thomas J.A. Snoeks, Isabel M. Mol, Ivo Que, Eric L. Kaijzel, and Clemens W.G.M. Lowik

883 Curcumin Inhibition of the Functional Interaction between Integrin α6β4 and the Epidermal Growth Factor Receptor
Young Hwa Soung and Jun Chung

888 Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A

892 Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment
Jianfeng Lu, Donna McEachern, Haiying Sun, Longchuan Bai, Yuefeng Peng, Su Qiu, Rebecca Miller, Jinhui Liao, Han Yi, Meilan Liu, Anita Bellail, Chunhai Hao, Shi-Yong Sun, Adrian T. Ting, and Shaomeng Wang

ABOUT THE COVER

Migration of hepatocellular carcinoma (HCC) cells that have undergone epithelial to mesenchymal transition (EMT). The 3sp cells transdifferentiated from malignant hepatocytes in the HCC patient via EMT show a migratory potential as determined by Platypus technology that can be modulated by pharmacological interference. Migrating cells are visualized by staining with CellTracker. For details, see article by van Zijl and colleagues on page 850.
Molecular Cancer Therapeutics

10 (5)

Mol Cancer Ther 2011;10:709-914.

| Updated version | Access the most recent version of this article at: http://mct.aacrjournals.org/content/10/5.citation |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |